{"id":"https://openalex.org/W4389233643","doi":"https://doi.org/10.1182/blood-2023-189761","title":"Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients","display_name":"Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389233643","doi":"https://doi.org/10.1182/blood-2023-189761"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-189761","doi":"https://doi.org/10.1182/blood-2023-189761","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-189761","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064556004","display_name":"Matthew J. Frigault","orcid":"https://orcid.org/0000-0002-6774-5694","observed_orcids":["https://orcid.org/0000-0002-6774-5694"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew J. Frigault","raw_affiliation_strings":["1Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054346063","display_name":"Jacalyn M. Rosenblatt","orcid":"https://orcid.org/0000-0001-5582-8161","observed_orcids":["https://orcid.org/0000-0001-5582-8161"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacalyn Rosenblatt","raw_affiliation_strings":["2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058783159","display_name":"Binod Dhakal","orcid":"https://orcid.org/0000-0002-4377-9742","observed_orcids":["https://orcid.org/0000-0002-4377-9742"]},"institutions":[{"id":"https://openalex.org/I204308271","display_name":"Medical College of Wisconsin","ror":"https://ror.org/00qqv6244","country_code":"US","type":"education","lineage":["https://openalex.org/I204308271"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Binod Dhakal","raw_affiliation_strings":["3BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI","institution_ids":["https://openalex.org/I204308271"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052048627","display_name":"Noopur S Raje","orcid":"https://orcid.org/0000-0003-3066-1275","observed_orcids":["https://orcid.org/0000-0003-3066-1275"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noopur S. Raje","raw_affiliation_strings":["4Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114029895","display_name":"Daniella Cook","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniella Cook","raw_affiliation_strings":["5Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003707145","display_name":"Mahmoud Gaballa","orcid":"https://orcid.org/0000-0002-3928-6590","observed_orcids":["https://orcid.org/0000-0002-3928-6590"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mahmoud Gaballa","raw_affiliation_strings":["5Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075220751","display_name":"Estelle Emmanuel\u2010Alejandro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Estelle Emmanuel-Alejandro","raw_affiliation_strings":["6Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089750700","display_name":"Danielle Nissen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204308271","display_name":"Medical College of Wisconsin","ror":"https://ror.org/00qqv6244","country_code":"US","type":"education","lineage":["https://openalex.org/I204308271"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle Nissen","raw_affiliation_strings":["7Medical College of Wisconsin, Milwaukee, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Medical College of Wisconsin, Milwaukee, WI","institution_ids":["https://openalex.org/I204308271"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046952743","display_name":"Kamalika C Banerjee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kamalika C Banerjee","raw_affiliation_strings":["8Arcellx Inc, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Arcellx Inc, Redwood City, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065261953","display_name":"Anand Rotte","orcid":"https://orcid.org/0000-0002-3452-7068","observed_orcids":["https://orcid.org/0000-0002-3452-7068"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anand Rotte","raw_affiliation_strings":["8Arcellx Inc, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Arcellx Inc, Redwood City, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104929572","display_name":"Christopher Ryan Heery","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher R Heery","raw_affiliation_strings":["8Arcellx Inc, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Arcellx Inc, Redwood City, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052641327","display_name":"David Avigan","orcid":"https://orcid.org/0000-0003-4624-6017","observed_orcids":["https://orcid.org/0000-0003-4624-6017"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Avigan","raw_affiliation_strings":["2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057911528","display_name":"Andrzej J. Jakubowiak","orcid":"https://orcid.org/0000-0002-2597-6822","observed_orcids":["https://orcid.org/0000-0002-2597-6822"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrzej J Jakubowiak","raw_affiliation_strings":["9University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089893290","display_name":"Michael Russell Bishop","orcid":"https://orcid.org/0000-0002-3979-9273","observed_orcids":["https://orcid.org/0000-0002-3979-9273"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Bishop","raw_affiliation_strings":["9University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"1023","last_page":"1023"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.8579000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.8579000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.13680000603199005,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.5830000042915344},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8989999890327454},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9369999766349792},{"id":"https://openalex.org/keywords/autologous-car-t-cells","display_name":"autologous CAR T cells","score":0.7509999871253967},{"id":"https://openalex.org/keywords/lymphodepletion-chemotherapy","display_name":"lymphodepletion chemotherapy","score":0.6840000152587891},{"id":"https://openalex.org/keywords/fludarabine-and-cyclophosphamide","display_name":"fludarabine and cyclophosphamide","score":0.8870000243186951},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.7400000095367432},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.890999972820282},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9779999852180481},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.6430000066757202},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4740000069141388},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.6600000262260437},{"id":"https://openalex.org/keywords/high-risk-multiple-myeloma","display_name":"high-risk myeloma","score":0.40700000524520874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8296802043914795},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6250123977661133},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5755770802497864},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.5570961833000183},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5543903708457947},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.45946216583251953},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.44139012694358826},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4374857544898987},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.42731526494026184},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4230969548225403},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.416256844997406},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34895622730255127},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3409639894962311},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-189761","doi":"https://doi.org/10.1182/blood-2023-189761","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-189761","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310107703","https://openalex.org/W4281607040","https://openalex.org/W4224440688","https://openalex.org/W3095496494","https://openalex.org/W4295817443","https://openalex.org/W4389247978","https://openalex.org/W2606328008","https://openalex.org/W3027582300","https://openalex.org/W2903951544","https://openalex.org/W2991241273"],"abstract_inverted_index":{"Introduction:":[0],"CART-ddBCMA,":[1,614],"an":[2,670],"autologous":[3],"anti-B-cell":[4],"maturation":[5],"antigen":[6,9],"(BCMA)":[7],"chimeric":[8],"receptor":[10],"(CAR)":[11],"T-cell":[12],"therapy":[13,78],"with":[14,31,69,273,359,404,421,457,483,556,601,613,647,661,669,678,693],"a":[15,24,83,236,312,591],"unique,":[16],"synthetic":[17],"binding":[18],"domain,":[19],"is":[20],"being":[21],"studied":[22],"in":[23,28,49,362,374,382,397,408,554,581,633,683],"first-in-human":[25],"clinical":[26,42,142,211,449,665,680],"trial":[27],"patients":[29,46,555,685],"(pts.)":[30],"relapsed":[32],"&/or":[33],"refractory":[34,261],"multiple":[35],"myeloma":[36],"(RRMM).":[37],"One-year":[38],"or":[39,438,563,628,656],"more":[40],"follow-up":[41,299,485,695],"data":[43,692],"from":[44,588],"all":[45,363,390],"are":[47,579,645],"presented":[48],"this":[50],"report.":[51],"Methods:":[52],"Details":[53],"of":[54,77,86,111,127,141,155,182,238,244,264,317,413,425,509,520,524,593,640,654,676],"study":[55],"design":[56],"have":[57,72,688],"been":[58],"previously":[59],"reported":[60],"(Frigault":[61],"et":[62],"al":[63],"Blood":[64],"Adv":[65],"2023).":[66],"Briefly,":[67],"pts":[68,214,248,258,267,281,288,377,399,446,527],"RRMM":[70],"who":[71,215],"received":[73,82,197],"\u22653":[74],"prior":[75,242],"lines":[76,243],"were":[79,120,177,194,205,216,224,250,255,260,357,368,393,441,502,514,543,551,619,631,667],"enrolled":[80],"&":[81,95,108,113,131,139,162,174,203,210,252,285,338,366,389,415,470,477,512,540,546,569,577,617,621,658],"single":[84],"infusion":[85,229,302],"CART-ddBCMA":[87,170,198,301,354],"following":[88],"lymphodepletion":[89],"chemotherapy":[90],"(fludarabine:":[91],"30":[92],"mg/m":[93,98],"2/d":[94,99],"cyclophosphamide:":[96],"300":[97,114],"daily":[100],"for":[101,152,207,227,494,537,605],"3":[102,387,471],"days).":[103],"Two":[104,213],"dose":[105,592],"levels":[106],"(DL1":[107],"DL2":[109,383],"respectively)":[110],"100":[112],"(\u00b120%)":[115],"\u00d710":[116,345,352,597],"6":[117,346,465,598],"CAR+":[118,309],"cells":[119,310,349],"evaluated.":[121,179],"The":[122,532],"primary":[123],"endpoints":[124,136],"included":[125,137],"incidence":[126],"adverse":[128],"events":[129,432,612,630],"(AEs)":[130],"dose-limiting":[132],"toxicities":[133],"(DLTs).":[134],"Additional":[135],"quality":[138],"duration":[140,508],"response":[143,450,653],"assessed":[144],"according":[145],"to":[146,169,231,262,479,497,687],"the":[147,360,364,518,586,589,606,634,638],"IMWG":[148,453],"Uniform":[149],"Response":[150],"Criteria":[151],"MM,":[153],"evaluation":[154],"minimal":[156],"residual":[157],"disease":[158],"(MRD),":[159],"progression-free":[160],"(PFS)":[161],"overall":[163,671],"survival":[164],"(OS).":[165],"Correlative":[166],"analyses":[167],"related":[168],"expansion,":[171],"characterization,":[172],"patient":[173],"disease-related":[175],"features":[176,558],"also":[178,552],"Results:":[180],"As":[181],"June":[183],"2,":[184,402],"2023,":[185],"40":[186],"pts;":[187],"median":[188,237,313,322,331,339],"age":[189],"66":[190],"years":[191],"(range:":[192,240,306,315,329,336,350],"44-76)":[193],"enrolled;":[195],"38":[196,204,444,525],"(32,":[199],"DL1;":[200],"6,":[201,538],"DL2)":[202],"evaluable":[206,445,493,526],"initial":[208],"safety":[209],"response.":[212,531],"not":[217,225,515],"dosed":[218],"had":[219,235,269,282,289,384,529],"cell":[220,228,332,340,427],"product":[221,355],"manufactured":[222],"but":[223,378],"eligible":[226],"due":[230],"medical":[232],"complications.":[233],"Pts":[234],"4":[239],"3-16)":[241],"therapy.":[245],"All":[246,411,443],"infused":[247],"(100%)":[249],"triple-refractory,":[251],"26":[253],"(68%)":[254],"penta-refractory;":[256],"34":[257],"(89%)":[259],"last-line":[263],"treatment;":[265],"9":[266],"(24%)":[268],"high":[270],"tumor":[271],"burden":[272],"\u226560%":[274],"bone":[275],"marrow":[276],"plasma":[277],"cells;":[278,321],"13":[279],"(34%)":[280],"extramedullary":[283],"disease;":[284],"11":[286],"(29%)":[287],"high-risk":[290,557,570],"cytogenetics":[291],"(Del":[292],"17p,":[293],"t(14;16),":[294],"t(4;14))":[295],"at":[296,504,517,567,574,637],"baseline.":[297],"Median":[298,507],"after":[300,435],"was":[303,326,334,343,481,603],"22":[304,458],"months":[305,542],"9-40":[307],"months).":[308],"comprised":[311],"70%":[314],"48-87%)":[316],"total":[318],"CD3+":[319],"T":[320],"vector":[323],"copy":[324],"number":[325],"2.2":[327],"copies/cell":[328],"1.1-3.5);":[330],"viability":[333],"98%":[335],"90-100%),":[337],"manufacturing":[341,370],"yield":[342],"1174":[344],"CAR":[347],"+":[348],"470-1626":[351],"6).":[353],"characteristics":[356],"consistent":[358,600],"specifications":[361],"lots,":[365],"there":[367],"no":[369,622],"failures.":[371],"CRS":[372,388,414,616],"occurred":[373,396],"36/38":[375],"(95%)":[376],"only":[379],"1":[380,405],"pt":[381],"grade":[385],"(Gr)":[386],"other":[391],"cases":[392,412,424],"Gr\u22642.":[394],"ICANS":[395,416],"7":[398,460],"(5,":[400],"Gr\u22642;":[401],"Gr3),":[403],"Gr3":[406],"case":[407],"each":[409],"DL.":[410],"resolved":[417],"without":[418],"further":[419],"sequalae":[420],"management.":[422],"No":[423],"off-tumor":[426,623],"mediated":[428],"toxicity,":[429,625],"delayed":[430,626],"neurotoxicity":[431],"(i.e.,":[433],"occurring":[434],"day":[436],"28),":[437],"Parkinsonian-like":[439,629],"symptoms":[440],"observed.":[442],"demonstrated":[447],"investigator-assessed":[448],"per":[451],"2016":[452],"criteria":[454],"(ORR,":[455],"100%)":[456],"sCR,":[459],"CR":[461],"(\u2265CR":[462],"rate,":[463,468],"76%),":[464],"VGPR":[466,655],"(\u2265VGPR":[467],"92%),":[469],"PR.":[472],"Responses":[473],"deepened":[474],"over":[475],"time":[476,519,639],"conversion":[478],"CR/sCR":[480],"observed":[482,553,632],"longer":[484],"(as":[486],"late":[487],"as":[488],"month":[489],"12).":[490],"Of":[491],"those":[492],"MRD":[495],"testing":[496],"date":[498],"(n=29),":[499],"25":[500,523],"(86%)":[501],"MRD-neg":[503],"10":[505,596],"-5.":[506],"response,":[510],"PFS,":[511],"OS":[513],"reached":[516],"data-cut":[521,699],"because":[522],"(66%)":[528],"ongoing":[530],"Kaplan-Meier":[533],"estimated":[534,672],"PFS":[535,572,674],"rates":[536,573],"12":[539],"18":[541],"92%,":[544],"74%,":[545],"67%":[547,677],"respectively.":[548],"Durable":[549],"responses":[550,666,681],"(EMD,":[559],"BMPC":[560],"\u2265":[561,565],"60%,":[562],"B2M":[564],"5.5":[566],"baseline)":[568],"cytogenetics.":[571],"6-,":[575],"12-,":[576],"18-months":[578],"shown":[580],"Table":[582],"1.":[583],"Based":[584],"on":[585,697],"results":[587,644],"study,":[590],"115":[594],"\u00b1":[595],"cells,":[599],"DL1,":[602],"recommended":[604],"phase":[607],"2":[608],"study.":[609],"Conclusions:":[610],"Adverse":[611],"including":[615,650],"ICANS,":[618],"manageable":[620],"tissue-targeted":[624],"neurotoxicity,":[627],"entire":[635],"cohort":[636],"data-cut.":[641],"Ongoing":[642],"efficacy":[643],"encouraging,":[646],"100%":[648],"ORR,":[649],"35":[651],"(92%)":[652],"better":[657],"29":[659],"(76%)":[660],"CR/sCR.":[662],"More":[663],"importantly,":[664],"durable":[668],"18-mo":[673],"rate":[675],"comparable":[679],"seen":[682],"\u2018high-risk\u2019":[684],"known":[686],"poor":[689],"prognosis.":[690],"Updated":[691],"additional":[694],"based":[696],"later":[698],"will":[700],"be":[701],"presented.":[702]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2023-12-02T00:00:00"}